Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA

Explore the safety considerations and unique toxicities of bispecific antibodies, including cytokine release syndrome and neurotoxicity management.

Explore the latest advancements in bispecific antibodies for multiple myeloma, focusing on early treatment opportunities and innovative trial designs.

Explore effective operational protocols for managing oncology patients, emphasizing multidisciplinary teamwork and proactive strategies to handle treatment toxicities.

Explore effective operational protocols for managing oncology patients, emphasizing multidisciplinary teamwork and proactive strategies to handle treatment toxicities.

Explore the operational challenges and solutions in administering bispecific therapies for follicular lymphoma, focusing on patient safety and education.

Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma with high response rates.

Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma with high response rates.

A recent ASH study highlights the impact of CAR T and bispecific therapies on patient time commitment and quality of life in treatment decisions.

Real-world evidence highlights the effectiveness of teclistamab and elranatamab in treating frail multiple myeloma patients, paving the way for future therapies.

Explore the latest insights on clinical trial data and real-world evidence for innovative cancer therapies, highlighting efficacy and safety.

Explore the promising role of Epcoritamab and bispecific therapies in second-line treatment for follicular lymphoma, enhancing patient outcomes.

Explore the unique mechanisms of bispecific antibodies and their rapid availability compared to CAR T-cell therapies in cancer treatment.

Explore the unique mechanisms of bispecific antibodies versus CAR T-cell therapies in treating multiple myeloma and their clinical implications.

Explore the promising role of Epcoritamab and bispecific therapies in second-line treatment for follicular lymphoma, enhancing patient outcomes.

Explore the latest insights on second-line therapies for follicular lymphoma, including the benefits and challenges of R2 treatment.

Explore the advancements in bispecific antibodies for follicular lymphoma, addressing treatment options, toxicities, and unmet patient needs in cancer care.

Explore the transformative potential of bispecific antibodies in multiple myeloma, offering hope for improved patient outcomes and possible cures.

Experts discuss the critical challenges in accessing innovative treatments for relapsed refractory multiple myeloma, emphasizing equity and education.

Explore innovative treatments for relapsed follicular lymphoma, focusing on novel therapies that enhance patient outcomes and reduce chemotherapy toxicity.

Experts discuss the critical challenges in accessing innovative treatments for relapsed refractory multiple myeloma, emphasizing equity and education.

Experts discuss the evolving role of bispecific antibodies in multiple myeloma, highlighting treatment advancements and strategies for optimal patient care.

Panelists discuss how AML treatment has entered an exciting era of personalized medicine with increasing oral options and targeted therapies, while identifying immunotherapy as a major unmet need and expressing optimism about patients achieving long-term survival on current regimens.

Panelists discuss how future AML treatment will likely involve sophisticated decisions about triplet combinations, optimal sequencing of targeted agents, and balancing efficacy with toxicity through either upfront intensive approaches or thoughtful sequential doublet therapies.

Panelists discuss how payer access challenges can determine whether patients receive therapy at all, with strategies including hospitalization for first cycles, advance prescription preparation, and recognition that oral regimens significantly impact quality of life for patients requiring lifelong treatment.

Panelists discuss how evolving policy reforms will reshape oncology research by balancing innovation, access, and affordability.

Panelists discuss how IRA-driven BTK inhibitor price changes could shift payer preferences, necessitating vigilance to preserve clinical integrity in treatment selection.

Panelists discuss how the IRA’s drug pricing reforms aim to improve affordability but may influence future oncology innovation.

Panelists discuss how integrating safety and access considerations into oncology policy can create more equitable, patient-centered coverage models.